S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
NASDAQ:HTGM

HTG Molecular Diagnostics - HTGM Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$3.50
$3.69
50-Day Range
$5.01
$6.80
52-Week Range
$3.50
$7.95
Volume
66,714 shs
Average Volume
107,006 shs
Market Capitalization
$3.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.83

HTG Molecular Diagnostics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
23.2% Downside
$2.83 Price Target
Short Interest
Healthy
6.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of HTG Molecular Diagnostics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($20.32) to ($3.61) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.22 out of 5 stars


HTGM stock logo

About HTG Molecular Diagnostics (NASDAQ:HTGM) Stock

HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.

Receive HTGM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HTG Molecular Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

HTGM Stock News Headlines

HTGM HTG Molecular Diagnostics, Inc.
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
HTG Announces One-for-Twelve Reverse Stock Split
HTG Molecular Diagnostics' Debt Overview
See More Headlines
Receive HTGM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HTG Molecular Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

HTGM Company Calendar

Last Earnings
11/10/2021
Today
3/28/2023
Next Earnings (Estimated)
4/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HTGM
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.83
High Stock Price Forecast
$3.50
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
-23.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-17,150,000.00
Net Margins
-324.66%
Pretax Margin
-324.53%

Debt

Sales & Book Value

Annual Sales
$8.91 million
Book Value
$16.45 per share

Miscellaneous

Free Float
896,000
Market Cap
$3.39 million
Optionable
Optionable
Beta
1.05

Key Executives

  • John L. Lubniewski
    President, Chief Executive Officer & Director
  • Shaun D. McMeans
    CFO, Secretary, Treasurer & SVP-Administration
  • Byron T. Lawson
    Chief Commercial Officer & Senior Vice President
  • Laura L. Godlewski
    Chief Accounting Officer & Vice President-Finance
  • Sam M. Rua
    Senior VP-Regulatory Affairs & Quality Systems













HTGM Stock - Frequently Asked Questions

Should I buy or sell HTG Molecular Diagnostics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HTGM shares.
View HTGM analyst ratings
or view top-rated stocks.

What is HTG Molecular Diagnostics' stock price forecast for 2023?

3 Wall Street analysts have issued 1-year price objectives for HTG Molecular Diagnostics' shares. Their HTGM share price forecasts range from $2.00 to $3.50. On average, they predict the company's stock price to reach $2.83 in the next twelve months. This suggests that the stock has a possible downside of 23.2%.
View analysts price targets for HTGM
or view top-rated stocks among Wall Street analysts.

Are investors shorting HTG Molecular Diagnostics?

HTG Molecular Diagnostics saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 48,300 shares, a decline of 55.8% from the February 28th total of 109,300 shares. Based on an average daily volume of 1,290,000 shares, the short-interest ratio is presently 0.0 days. Approximately 6.6% of the shares of the stock are short sold.
View HTG Molecular Diagnostics' Short Interest
.

When is HTG Molecular Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our HTGM earnings forecast
.

How were HTG Molecular Diagnostics' earnings last quarter?

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) announced its earnings results on Wednesday, November, 10th. The medical research company reported ($0.60) earnings per share for the quarter, hitting the consensus estimate of ($0.60). The medical research company had revenue of $2.52 million for the quarter, compared to the consensus estimate of $2.90 million. HTG Molecular Diagnostics had a negative trailing twelve-month return on equity of 310.67% and a negative net margin of 324.66%. During the same period in the previous year, the company posted ($1.05) earnings per share.

What guidance has HTG Molecular Diagnostics issued on next quarter's earnings?

HTG Molecular Diagnostics issued an update on its FY 2022 earnings guidance on Friday, January, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $6.40 million-$6.40 million, compared to the consensus revenue estimate of $5.70 million.

What is Tim (TJ) Johnson's approval rating as HTG Molecular Diagnostics' CEO?

11 employees have rated HTG Molecular Diagnostics Chief Executive Officer Tim (TJ) Johnson on Glassdoor.com. Tim (TJ) Johnson has an approval rating of 47% among the company's employees. This puts Tim (TJ) Johnson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of HTG Molecular Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Biocept (BIOC), Rigel Pharmaceuticals (RIGL), Heat Biologics (HTBX), MEI Pharma (MEIP), Zosano Pharma (ZSAN), Verastem (VSTM), Aurinia Pharmaceuticals (AUPH), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did HTG Molecular Diagnostics IPO?

(HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is HTG Molecular Diagnostics' stock symbol?

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

Who are HTG Molecular Diagnostics' major shareholders?

HTG Molecular Diagnostics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

What is HTG Molecular Diagnostics' stock price today?

One share of HTGM stock can currently be purchased for approximately $3.69.

How much money does HTG Molecular Diagnostics make?

HTG Molecular Diagnostics (NASDAQ:HTGM) has a market capitalization of $3.39 million and generates $8.91 million in revenue each year. The medical research company earns $-17,150,000.00 in net income (profit) each year or ($29.4118) on an earnings per share basis.

How can I contact HTG Molecular Diagnostics?

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The official website for the company is www.htgmolecular.com. The medical research company can be reached via phone at (520) 547-2827, via email at arr@lifesciadvisors.com, or via fax at 520-547-2837.

This page (NASDAQ:HTGM) was last updated on 3/29/2023 by MarketBeat.com Staff